StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
CLRBBullishEarningsnews
High materiality8/10

Cellectar advances Waldenström program with Phase 3 kickoff and 2027 NDA plan

Aug 13, 2026, 7:18 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

The combination of a cleared runway into 2027, confirmatory Phase 3 WM site activation, and a mid-2027 NDA could drive upside for CLRB if data remain compelling; near-term catalysts (data readouts, webinar, and financing) can attract attention, though dilution risk from the offering may cap gains.

AI summary

What happened, with direct paths to the underlying reporting

Cellectar Biosciences reported Q2 2026 results with $34 million in cash and a narrowed loss, while advancing key catalysts: site activation for a confirmatory Phase 3 iopofosine I-131 trial in Waldenström macroglobulinemia and a mid-2027 NDA under FDA Accelerated Approval. Supporting data from CLOVER WaM and ongoing CLR 125 TNBC progress underscore near-term momentum, though funding activity introduces dilution risk.

  • CLRB Q2 2026: cash $34.0M; net loss $6.93M.
  • Phase 3 iopofosine I-131 in WM: site activation; NDA planned mid-2027.
  • CLOVER WaM data in WM show high ORR; supports accelerated approval path.
  • CLR 125 TNBC: Phase 1b enrollment/dosing advanced; data readouts anticipated.
  • May 2026 financing: $35M upfront; up to $105M milestones to fund programs.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event